ACCF/AHA methodology for the development of quality measures for cardiovascular technology: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures

Robert O. Bonow, Pamela S. Douglas, Alfred E. Buxton, David J. Cohen, Jeptha P. Curtis, Elizabeth Delong, Joseph P. Drozda, T. Bruce Ferguson, Paul A. Heidenreich, Robert Hendel, Frederick A. Masoudi, Eric D. Peterson, Allen J. Taylor

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Summary Statement-Consistent with the growing national focus on healthcare quality, the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have taken a leadership role over the past decade in developing measures of the quality of cardiovascular care by convening a joint ACCF/AHA Task Force on Performance Measures. The Task Force is charged with identifying the clinical topics appropriate for the development of performance measures and with assembling writing committees composed of clinical and methodological experts in collaboration with appropriate subspecialty societies. The Task Force has also created methodology documents that offer guidance in the development of process, outcome, composite, and efficiency measures. Cardiovascular performance measures using existing ACCF/AHA methodology are based on Class I or Class III guidelines recommendations, usually with Level A evidence. These performance measures, based on evidence-based ACCF/AHA guidelines, remain the most rigorous quality measures for both internal quality improvement and public reporting.However, many of the tools for diagnosis and treatment of cardiovascular disease involve advanced technologies, such as cardiac imaging, for which there are often no underlying guideline documents. Because these technologies affect the quality of cardiovascular care and also have the potential to contribute to cardiovascular health expenditures, there is a need for more critical assessment of the use of technology, including the development of quality and performance measures in areas in which guideline recommendations are absent.The evaluation of quality in the use of cardiovascular technologies requires consideration of multiple parameters that differ from other healthcare processes. The present document describes methodology for development of 2 new classes of quality measures in these situations, appropriate use measures and structure/safety measures. Appropriate use measures are based on specific indications, processes, or parameters of care for which high level of evidence data and Class I or Class III guideline recommendations may be lacking but are addressed in ACCF appropriate use criteria documents. Structure/safety measures represent measures developed to address structural aspects of the use of healthcare technology (eg, laboratory accreditation, personnel training, and credentialing) or quality issues related to patient safety when there are neither guidelines recommendations nor appropriate use criteria. Although the strength of evidence for appropriate use measures and structure/safety measures may not be as strong as that for formal performance measures, they are quality measures that are otherwise rigorously developed, reviewed, tested, and approved in the same manner as ACCF/AHA performance measures.The ultimate goal of the present document is to provide direction in defining and measuring the appropriate use-avoiding not only underuse but also overuse and misuse-and proper application of cardiovascular technology and to describe how such appropriate use measures and structure/safety measures might be developed for the purposes of quality improvement and public reporting. It is anticipated that this effort will help focus the national dialogue on the use of cardiovascular technology and away from the current concerns about volume and cost alone to a more holistic emphasis on value.

Original languageEnglish
Pages (from-to)1483-1502
Number of pages20
JournalCirculation
Volume124
Issue number13
DOIs
StatePublished - Sep 27 2011
Externally publishedYes

Fingerprint

American Heart Association
Advisory Committees
Cardiology
Guidelines
Technology
Quality of Health Care
Safety
Quality Improvement
Credentialing
Delivery of Health Care
Laboratory Personnel
Biomedical Technology Assessment
Accreditation
Patient Safety
Health Expenditures
Cardiovascular Diseases
Joints
Costs and Cost Analysis

Keywords

  • AHA Scientific Statements
  • quality assessment, healthcare
  • quality indicators, healthcare
  • technology, medical

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

ACCF/AHA methodology for the development of quality measures for cardiovascular technology : A report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures. / Bonow, Robert O.; Douglas, Pamela S.; Buxton, Alfred E.; Cohen, David J.; Curtis, Jeptha P.; Delong, Elizabeth; Drozda, Joseph P.; Ferguson, T. Bruce; Heidenreich, Paul A.; Hendel, Robert; Masoudi, Frederick A.; Peterson, Eric D.; Taylor, Allen J.

In: Circulation, Vol. 124, No. 13, 27.09.2011, p. 1483-1502.

Research output: Contribution to journalArticle

Bonow, RO, Douglas, PS, Buxton, AE, Cohen, DJ, Curtis, JP, Delong, E, Drozda, JP, Ferguson, TB, Heidenreich, PA, Hendel, R, Masoudi, FA, Peterson, ED & Taylor, AJ 2011, 'ACCF/AHA methodology for the development of quality measures for cardiovascular technology: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures', Circulation, vol. 124, no. 13, pp. 1483-1502. https://doi.org/10.1161/CIR.0b013e31822935fc
Bonow, Robert O. ; Douglas, Pamela S. ; Buxton, Alfred E. ; Cohen, David J. ; Curtis, Jeptha P. ; Delong, Elizabeth ; Drozda, Joseph P. ; Ferguson, T. Bruce ; Heidenreich, Paul A. ; Hendel, Robert ; Masoudi, Frederick A. ; Peterson, Eric D. ; Taylor, Allen J. / ACCF/AHA methodology for the development of quality measures for cardiovascular technology : A report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures. In: Circulation. 2011 ; Vol. 124, No. 13. pp. 1483-1502.
@article{08ab1fa3827d4973a77666d1f3329814,
title = "ACCF/AHA methodology for the development of quality measures for cardiovascular technology: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures",
abstract = "Summary Statement-Consistent with the growing national focus on healthcare quality, the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have taken a leadership role over the past decade in developing measures of the quality of cardiovascular care by convening a joint ACCF/AHA Task Force on Performance Measures. The Task Force is charged with identifying the clinical topics appropriate for the development of performance measures and with assembling writing committees composed of clinical and methodological experts in collaboration with appropriate subspecialty societies. The Task Force has also created methodology documents that offer guidance in the development of process, outcome, composite, and efficiency measures. Cardiovascular performance measures using existing ACCF/AHA methodology are based on Class I or Class III guidelines recommendations, usually with Level A evidence. These performance measures, based on evidence-based ACCF/AHA guidelines, remain the most rigorous quality measures for both internal quality improvement and public reporting.However, many of the tools for diagnosis and treatment of cardiovascular disease involve advanced technologies, such as cardiac imaging, for which there are often no underlying guideline documents. Because these technologies affect the quality of cardiovascular care and also have the potential to contribute to cardiovascular health expenditures, there is a need for more critical assessment of the use of technology, including the development of quality and performance measures in areas in which guideline recommendations are absent.The evaluation of quality in the use of cardiovascular technologies requires consideration of multiple parameters that differ from other healthcare processes. The present document describes methodology for development of 2 new classes of quality measures in these situations, appropriate use measures and structure/safety measures. Appropriate use measures are based on specific indications, processes, or parameters of care for which high level of evidence data and Class I or Class III guideline recommendations may be lacking but are addressed in ACCF appropriate use criteria documents. Structure/safety measures represent measures developed to address structural aspects of the use of healthcare technology (eg, laboratory accreditation, personnel training, and credentialing) or quality issues related to patient safety when there are neither guidelines recommendations nor appropriate use criteria. Although the strength of evidence for appropriate use measures and structure/safety measures may not be as strong as that for formal performance measures, they are quality measures that are otherwise rigorously developed, reviewed, tested, and approved in the same manner as ACCF/AHA performance measures.The ultimate goal of the present document is to provide direction in defining and measuring the appropriate use-avoiding not only underuse but also overuse and misuse-and proper application of cardiovascular technology and to describe how such appropriate use measures and structure/safety measures might be developed for the purposes of quality improvement and public reporting. It is anticipated that this effort will help focus the national dialogue on the use of cardiovascular technology and away from the current concerns about volume and cost alone to a more holistic emphasis on value.",
keywords = "AHA Scientific Statements, quality assessment, healthcare, quality indicators, healthcare, technology, medical",
author = "Bonow, {Robert O.} and Douglas, {Pamela S.} and Buxton, {Alfred E.} and Cohen, {David J.} and Curtis, {Jeptha P.} and Elizabeth Delong and Drozda, {Joseph P.} and Ferguson, {T. Bruce} and Heidenreich, {Paul A.} and Robert Hendel and Masoudi, {Frederick A.} and Peterson, {Eric D.} and Taylor, {Allen J.}",
year = "2011",
month = "9",
day = "27",
doi = "10.1161/CIR.0b013e31822935fc",
language = "English",
volume = "124",
pages = "1483--1502",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "13",

}

TY - JOUR

T1 - ACCF/AHA methodology for the development of quality measures for cardiovascular technology

T2 - A report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures

AU - Bonow, Robert O.

AU - Douglas, Pamela S.

AU - Buxton, Alfred E.

AU - Cohen, David J.

AU - Curtis, Jeptha P.

AU - Delong, Elizabeth

AU - Drozda, Joseph P.

AU - Ferguson, T. Bruce

AU - Heidenreich, Paul A.

AU - Hendel, Robert

AU - Masoudi, Frederick A.

AU - Peterson, Eric D.

AU - Taylor, Allen J.

PY - 2011/9/27

Y1 - 2011/9/27

N2 - Summary Statement-Consistent with the growing national focus on healthcare quality, the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have taken a leadership role over the past decade in developing measures of the quality of cardiovascular care by convening a joint ACCF/AHA Task Force on Performance Measures. The Task Force is charged with identifying the clinical topics appropriate for the development of performance measures and with assembling writing committees composed of clinical and methodological experts in collaboration with appropriate subspecialty societies. The Task Force has also created methodology documents that offer guidance in the development of process, outcome, composite, and efficiency measures. Cardiovascular performance measures using existing ACCF/AHA methodology are based on Class I or Class III guidelines recommendations, usually with Level A evidence. These performance measures, based on evidence-based ACCF/AHA guidelines, remain the most rigorous quality measures for both internal quality improvement and public reporting.However, many of the tools for diagnosis and treatment of cardiovascular disease involve advanced technologies, such as cardiac imaging, for which there are often no underlying guideline documents. Because these technologies affect the quality of cardiovascular care and also have the potential to contribute to cardiovascular health expenditures, there is a need for more critical assessment of the use of technology, including the development of quality and performance measures in areas in which guideline recommendations are absent.The evaluation of quality in the use of cardiovascular technologies requires consideration of multiple parameters that differ from other healthcare processes. The present document describes methodology for development of 2 new classes of quality measures in these situations, appropriate use measures and structure/safety measures. Appropriate use measures are based on specific indications, processes, or parameters of care for which high level of evidence data and Class I or Class III guideline recommendations may be lacking but are addressed in ACCF appropriate use criteria documents. Structure/safety measures represent measures developed to address structural aspects of the use of healthcare technology (eg, laboratory accreditation, personnel training, and credentialing) or quality issues related to patient safety when there are neither guidelines recommendations nor appropriate use criteria. Although the strength of evidence for appropriate use measures and structure/safety measures may not be as strong as that for formal performance measures, they are quality measures that are otherwise rigorously developed, reviewed, tested, and approved in the same manner as ACCF/AHA performance measures.The ultimate goal of the present document is to provide direction in defining and measuring the appropriate use-avoiding not only underuse but also overuse and misuse-and proper application of cardiovascular technology and to describe how such appropriate use measures and structure/safety measures might be developed for the purposes of quality improvement and public reporting. It is anticipated that this effort will help focus the national dialogue on the use of cardiovascular technology and away from the current concerns about volume and cost alone to a more holistic emphasis on value.

AB - Summary Statement-Consistent with the growing national focus on healthcare quality, the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have taken a leadership role over the past decade in developing measures of the quality of cardiovascular care by convening a joint ACCF/AHA Task Force on Performance Measures. The Task Force is charged with identifying the clinical topics appropriate for the development of performance measures and with assembling writing committees composed of clinical and methodological experts in collaboration with appropriate subspecialty societies. The Task Force has also created methodology documents that offer guidance in the development of process, outcome, composite, and efficiency measures. Cardiovascular performance measures using existing ACCF/AHA methodology are based on Class I or Class III guidelines recommendations, usually with Level A evidence. These performance measures, based on evidence-based ACCF/AHA guidelines, remain the most rigorous quality measures for both internal quality improvement and public reporting.However, many of the tools for diagnosis and treatment of cardiovascular disease involve advanced technologies, such as cardiac imaging, for which there are often no underlying guideline documents. Because these technologies affect the quality of cardiovascular care and also have the potential to contribute to cardiovascular health expenditures, there is a need for more critical assessment of the use of technology, including the development of quality and performance measures in areas in which guideline recommendations are absent.The evaluation of quality in the use of cardiovascular technologies requires consideration of multiple parameters that differ from other healthcare processes. The present document describes methodology for development of 2 new classes of quality measures in these situations, appropriate use measures and structure/safety measures. Appropriate use measures are based on specific indications, processes, or parameters of care for which high level of evidence data and Class I or Class III guideline recommendations may be lacking but are addressed in ACCF appropriate use criteria documents. Structure/safety measures represent measures developed to address structural aspects of the use of healthcare technology (eg, laboratory accreditation, personnel training, and credentialing) or quality issues related to patient safety when there are neither guidelines recommendations nor appropriate use criteria. Although the strength of evidence for appropriate use measures and structure/safety measures may not be as strong as that for formal performance measures, they are quality measures that are otherwise rigorously developed, reviewed, tested, and approved in the same manner as ACCF/AHA performance measures.The ultimate goal of the present document is to provide direction in defining and measuring the appropriate use-avoiding not only underuse but also overuse and misuse-and proper application of cardiovascular technology and to describe how such appropriate use measures and structure/safety measures might be developed for the purposes of quality improvement and public reporting. It is anticipated that this effort will help focus the national dialogue on the use of cardiovascular technology and away from the current concerns about volume and cost alone to a more holistic emphasis on value.

KW - AHA Scientific Statements

KW - quality assessment, healthcare

KW - quality indicators, healthcare

KW - technology, medical

UR - http://www.scopus.com/inward/record.url?scp=80053335041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053335041&partnerID=8YFLogxK

U2 - 10.1161/CIR.0b013e31822935fc

DO - 10.1161/CIR.0b013e31822935fc

M3 - Article

C2 - 21875906

AN - SCOPUS:80053335041

VL - 124

SP - 1483

EP - 1502

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 13

ER -